Does the Diameter of Dextranomer Microspheres Affect the Success in Endoscopic Treatment of Vesicoureteral Reflux?

Aydoğdu, Özgü; Özcan, Cihat; Burgu, Berk; Mermerkaya, Murat; Soygür, Tarkan

doi:10.1016/j.urology.2012.05.018

Cited by 9 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently a similar compound (Dexell) has been produced, which is biochemically similar to Deflux with a different molecular size. Two articles documented the use of Dexell with comparable results with Deflux, indicating the indifference of their molecular sizes in the success rate of ET (16,17).…”

Section: Discussionmentioning

confidence: 99%

“…Deflux has dextranomer microspheres ranging in size from 80 to 250 microns (an average size of 130 microns) while the size of Dexell dextranomer microsphere is 80 to 120 microns. Therapeutically, no significant difference in the outcome of these two agents has been found (16,17). The ideal injectable bulking agent should be durable, effective, safe, stable, none migrating, biocompatible, noneantigenic, and none-carcinogenic (18,19).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

Jaafar

Hussein

2016

Int J Infect

View full text Add to dashboard Cite

Background: Recurrent urinary tract infection (UTI) due to vesicoureteral reflux (VUR) is common in Iraq. Endoscopic treatment of VUR is used with advantages over antibiotic prophylaxis and ureteral reimplantation. Objectives: This study was performed to assess the efficacy of a new agent, Dexell, for treating patients with VUR and its ability to manage recurrent UTI. Materials and Methods:This research was a prospective study recruiting 156 patients with VUR treated by endoscopic subureteric injection of Dexell. Results: VUR were unilateral in 87 cases and bilateral in 69 cases. VUR grades II-V were 18.7%, 28%, 32%, and 21.3%, respectively. The success rates were 64% after the first injection, 82.7% after second injection, and 93.3% after third injection. All patients with grades II and III were resolved completely while the success rates in higher grades were 91.7% for grade IV and 87.5% for grade V. No significant difference was noted between males and females regarding the success rate of endoscopic treatment (92% vs 91.6%, P > 0.05). Recurrent UTI did not occur throughout the study period after the operation. Conclusions: Cystoscopic injection of Dexell is an effective method for treating patients with VUR. It is a safe day case procedure that can prevent recurrent UTI in patients with VUR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

Jaafar

Hussein

2016

Int J Infect

View full text Add to dashboard Cite

show abstract

“…Urodex includes positive loaded dextranomer, so the material causes a durable tissue reaction with immediate collagen formation and can remain in the tissue for a long time. Besides, Urodex is quite cheaper than Deflux in Turkey [12]. The price of Deflux is 300$ and those of Urodex and Vurdex are 150$ in Turkey.…”

Section: Discussionmentioning

confidence: 99%

“…Dx/HA has different commercial names, according to the size of the contained microspheres. Deflux contains 80–250 μ m dextranomer microspheres and in products like Urodex® Dexell has a size of 80–120 μ m [12]. …”

Section: Introductionmentioning

confidence: 99%

Subureteral Injection with Small-Size Dextranomer/Hyaluronic Acid Copolymer: Is It Really Efficient?

Üre

Gürocak

Tan

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

The aim of this study was to evaluate the clinical results of patients with vesicoureteral reflux, which were treated with subureteral injection of small-size (80–120 μm) dextranomer/hyaluronic acid copolymer (Dx/HA). Data of 75 children (105 renal units) who underwent STING procedure with small-size Dx/HA for the treatment of vesicoureteral reflux (VUR) in our clinic between 2008 and 2012 were retrospectively analyzed. Preoperative reflux grade and side, injection indication, postoperative urinary infections and urinary symptoms, voiding cystourethrogram, and renal scintigraphy results were evaluated. The success rate of the procedure was 100% in patients with grades 1 and 2 reflux, 91% in patients with grade 3 reflux, and 82.6% in patients with grade 4. Overall success rate of the treated patients was 97%. Endoscopic subureteric injection with Dx/HA procedure has become a reasonable minimally invasive alternative technique to open surgery, long-term antibiotic prophylaxis, and surveillance modalities in treatment of VUR in terms of easy application, low costs and complication rates, and high success rates. Injection material composed of small-size dextranomer microspheres seems superior to normal size Dx/HA, together with offering similar success with low cost.

show abstract

“…[3][4][5][6][7][8][9][10][11][12] Why the discrepancy? Retrospective studies designed to report surgical success of injections were likely limited in followup, had variable definitions of UTI and may not have evaluated urine cultures obtained outside the treating institutions.…”

mentioning

confidence: 99%

Risk of Febrile Urinary Tract Infection After Reflux Surgery—Does the Type of Procedure Matter?

Bush

2013

Journal of Urology

View full text Add to dashboard Cite

Does the Diameter of Dextranomer Microspheres Affect the Success in Endoscopic Treatment of Vesicoureteral Reflux?

Cited by 9 publications

References 16 publications

Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

Subureteral Injection with Small-Size Dextranomer/Hyaluronic Acid Copolymer: Is It Really Efficient?

Risk of Febrile Urinary Tract Infection After Reflux Surgery—Does the Type of Procedure Matter?

Contact Info

Product

Resources

About